Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Allergy and Asthma Reports
Erschienen in: Current Allergy and Asthma Reports 5/2015

01.05.2015 | Immunotherapy and Immunomodulators (B Vickery, Section Editor)

Is Clinical Tolerance Possible after Allergen Immunotherapy?

verfasst von: Timothy P. Moran, A. Wesley Burks

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

There is a growing evidence that allergen immunotherapy (AIT) can provide significant and long-lasting clinical benefit for a number of allergic individuals. However, it is less clear if AIT results in clinical tolerance, which is characterized by a persistent state of clinical non-reactivity to allergens after therapy is finished. Addressing this knowledge gap is particularly relevant for patients undergoing AIT for food allergies, as anything less than complete tolerance could have potentially devastating consequences. An increasing number of studies, in particular those involving oral immunotherapy, are attempting to assess tolerance induction following AIT. Clinical tolerance does appear to be achievable in a subset of patients undergoing AIT, but whether this is equivalent to the type of tolerance observed in nonallergic individuals remains unknown. Developing established criteria for assessing tolerance induction, as well as the use of consistent terminology when describing clinical tolerance, will be important for determining the disease-modifying potential of AIT.
Literatur
1.
Cox L et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(1 Suppl):S1–55.PubMedCrossRef
2.
Boyle RJ et al. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database Syst Rev. 2012;10:Cd008838.PubMed
3.
Calderon MA, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007(1): p. Cd001936.
4.
Abramson MJ, Puy RM, and Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010(8): p. Cd001186.
5.
Radulovic S. et al. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010(12): p. Cd002893.
6.
Moran TP, Vickery BP, Burks AW. Oral and sublingual immunotherapy for food allergy: current progress and future directions. Curr Opin Immunol. 2013;25(6):781–7.PubMedCentralPubMedCrossRef
7.
Burks AW et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013;131(5):1288–96.PubMedCrossRef
8.
Berin MC, Mayer L. Can we produce true tolerance in patients with food allergy? J Allergy Clin Immunol. 2013;131(1):14–22.PubMedCrossRef
9.
Novak N et al. Early suppression of basophil activation during allergen-specific immunotherapy by histamine receptor 2. J Allergy Clin Immunol. 2012;130(5):1153–1158.PubMedCrossRef
10.
Soyer OU et al. Mechanisms of peripheral tolerance to allergens. Allergy. 2013;68(2):161–70.PubMedCrossRef
11.
Platts-Mills TA, Woodfolk JA. Allergens and their role in the allergic immune response. Immunol Rev. 2011;242(1):51–68.PubMedCrossRef
12.
13.
Akdis M et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med. 2004;199(11):1567–75.PubMedCentralPubMedCrossRef
14.
Platts-Mills T et al. Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study. Lancet. 2001;357(9258):752–6.PubMedCrossRef
15.
van de Veen W et al. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J Allergy Clin Immunol. 2013;131(4):1204–12.PubMedCrossRef
16.
Kretschmer K et al. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol. 2005;6(12):1219–27.PubMedCrossRef
17.
18.
Karlsson MR, Rugtveit J, Brandtzaeg P. Allergen-responsive CD4+CD25+ regulatory T cells in children who have outgrown cow's milk allergy. J Exp Med. 2004;199(12):1679–88.PubMedCentralPubMedCrossRef
19.
James JM, Sampson HA. Immunologic changes associated with the development of tolerance in children with cow milk allergy. J Pediatr. 1992;121(3):371–7.PubMedCrossRef
20.
Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol. 2014;133(3):621–31.PubMedCrossRef
21.
22.
Cox L, Cohn JR. Duration of allergen immunotherapy in respiratory allergy: when is enough, enough? Ann Allergy Asthma Immunol. 2007;98(5):416–26.PubMedCrossRef
23.••
Burks AW et al. Oral immunotherapy for treatment of egg allergy in children. N Engl J Med. 2012;367(3):233–43. This is the first study to demonstrate sustained unresponsiveness in food allergic subjects who had completed OIT. PubMedCentralPubMedCrossRef
24.
Buchanan AD et al. Egg oral immunotherapy in nonanaphylactic children with egg allergy. J Allergy Clin Immunol. 2007;119(1):199–205.PubMedCrossRef
25.
Vickery BP et al. Individualized IgE-based dosing of egg oral immunotherapy and the development of tolerance. Ann Allergy Asthma Immunol. 2010;105(6):444–50.PubMedCentralPubMedCrossRef
26.
27.•
Keet CA et al. Long-term follow-up of oral immunotherapy for cow's milk allergy. J Allergy Clin Immunol. 2013;132(3):737–739. This brief report describes clinical outcomes in patients up to 5 years following OIT for cow's milk allergy. PubMedCentralPubMedCrossRef
28.
Staden U et al. Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction. Allergy. 2007;62(11):1261–9.PubMedCrossRef
29.•
Vickery BP et al. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. J Allergy Clin Immunol. 2014;133(2):468–75. This is the first report of sustained unresponsiveness in peanut-allergic patients after OIT. PubMedCentralPubMedCrossRef
30.
31.•
Syed A et al. Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). J Allergy Clin Immunol. 2014;133(2):500–10. This study evaluated clinical tolerance in peaut-allergic patients 6 months after completing OIT. PubMedCentralPubMedCrossRef
32.
Chin SJ. et al. Sublingual versus oral immunotherapy for peanut-allergic children: A retrospective comparison. J Allergy Clin Immunol. 2013;132(2):476-8.
33.
Naclerio RM et al. A double-blind study of the discontinuation of ragweed immunotherapy. J Allergy Clin Immunol. 1997;100(3):293–300.PubMedCrossRef
34.
Durham SR et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999;341(7):468–75.PubMedCrossRef
35.
Jacobsen L et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62(8):943–8.PubMedCrossRef
36.
Tabar AI et al. Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy. J Allergy Clin Immunol. 2011;127(1):57–63.PubMedCrossRef
37.
Durham SR et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol. 2010;125(1):131–8.PubMedCrossRef
38.•
Durham SR et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129(3):717–725. This report describes that the clinical benefits of SLIT for pollen allergy can persist for at least 2 years after stopping therapy. PubMedCrossRef
39.
James LK et al. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol. 2011;127(2):509–516.PubMedCrossRef
40.
Didier A et al. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol. 2011;128(3):559–66.PubMedCrossRef
41.
Didier A et al. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis. Clin Exp Allergy. 2013;43(5):568–77.PubMedCrossRef
42.•
Bergmann KC et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol. 2014;133(6):1608–14. This reference reports that SLIT for house dust mite allergy can result in clinical benefit that is sustained for at least 1 year following therapy. PubMedCrossRef
43.
Patel D et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol. 2013;131(1):103–9.PubMedCrossRef
44.
Senti G et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A. 2008;105(46):17908–12.PubMedCentralPubMedCrossRef
45.
Senti G et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol. 2012;129(5):1290–6.PubMedCrossRef
46.
Witten M et al. Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? J Allergy Clin Immunol. 2013;132(5):1248–1252.PubMedCrossRef
47.
Golden DB et al. Stinging insect hypersensitivity: a practice parameter update 2011. J Allergy Clin Immunol. 2011;127(4):852–4.PubMedCrossRef
48.
Golden DB et al. Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol. 1996;97(2):579–87.PubMedCrossRef
49.
Golden DB, Kagey-Sobotka A, Lichtenstein LM. Survey of patients after discontinuing venom immunotherapy. J Allergy Clin Immunol. 2000;105(2 Pt 1):385–90.PubMedCrossRef
50.
Lerch E, Muller UR. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. J Allergy Clin Immunol. 1998;101(5):606–12.PubMedCrossRef
51.
Golden DB et al. Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med. 2004;351(7):668–74.PubMedCrossRef
52.
Stritzke AI, Eng PA. Age-dependent sting recurrence and outcome in immunotherapy-treated children with anaphylaxis to Hymenoptera venom. Clin Exp Allergy. 2013;43(8):950–5.PubMedCrossRef
Metadaten
Titel
Is Clinical Tolerance Possible after Allergen Immunotherapy?
verfasst von
Timothy P. Moran
A. Wesley Burks
Publikationsdatum
01.05.2015
Verlag
Springer US
Erschienen in
Current Allergy and Asthma Reports / Ausgabe 5/2015
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-015-0523-3

Weitere Artikel der Ausgabe 5/2015

Current Allergy and Asthma Reports 5/2015 Zur Ausgabe

Immune Deficiency and Dysregulation (DP Huston, Section Editor)

Microbiota Metabolite Regulation of Host Immune Homeostasis: A Mechanistic Missing Link

Autoimmunity (TK Tarrant, Section Editor)

Update on Systemic Sclerosis

Allergens (RK Bush and JA Woodfolk, Section Editors)

Severe Asthma in School-Age Children: Evaluation and Phenotypic Advances

Rhinosinusitis (J Mullol, Section Editor)

Clinical and Biological Markers of Difficult-to-Treat Severe Chronic Rhinosinusitis

Immunologic/Diagnostic Tests in Allergy (M Chapman and A Pomés, Section Editors)

Anaphylaxis to Insect Venom Allergens: Role of Molecular Diagnostics

Anaphylaxis and Drug Allergy (DA Khan and M Castells, Section Editors)

Cutaneous and Systemic Mastocytosis in Children: A Risk Factor for Anaphylaxis?

Neu im Fachgebiet HNO

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

HNO-Op. auch mit über 90?

16.04.2024 HNO-Chirurgie Nachrichten

Mit Blick auf das Risiko für Komplikationen nach elektiven Eingriffen im HNO-Bereich scheint das Alter der Patienten kein ausschlaggebender Faktor zu sein. Entscheidend ist offenbar, wie fit die Betroffenen tatsächlich sind.

Intrakapsuläre Tonsillektomie gewinnt an Boden

16.04.2024 Tonsillektomie Nachrichten

Gegenüber der vollständigen Entfernung der Gaumenmandeln hat die intrakapsuläre Tonsillektomie einige Vorteile, wie HNO-Fachleute aus den USA hervorheben. Sie haben die aktuelle Literatur zu dem Verfahren gesichtet.

Bilateraler Hörsturz hat eine schlechte Prognose

15.04.2024 Hörsturz Nachrichten

Die Mehrzahl der Menschen mit Hörsturz ist einseitig betroffen, doch auch ein beidseitiger Hörsturz ist möglich. Wie häufig solche Fälle sind und wie sich ihr Verlauf darstellt, hat eine HNO-Expertenrunde aus den USA untersucht.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise